Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS pr...(o certain operating risks that may cause...)

Date:5/19/2009

o certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements containe
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
2. Angiotech announces date of annual general meeting of shareholders
3. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Angiotech announces positive results from Bio-Seal(TM) clinical study
6. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
7. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
8. Angiotech Pharmaceuticals announces time change of conference call and webcast
9. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
10. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
11. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014